Controlling distinct signaling states in cultured cancer cells provides a new platform for drug discovery.
Poser SW, Otto O, Arps-Forker C, Ge Y, Herbig M, Andree C, Gruetzmann K, Adasme MF, Stodolak S, Nikolakopoulou P, Park DM, Mcintyre A, Lesche M, Dahl A, Lennig P, Bornstein SR, Schroeck E, Klink B, Leker RR, Bickle M, Chrousos GP, Schroeder M, Cannistraci CV, Guck J, Androutsellis-Theotokis A.
Poser SW, et al. Among authors: dahl a.
FASEB J. 2019 Aug;33(8):9235-9249. doi: 10.1096/fj.201802603RR. Epub 2019 May 30.
FASEB J. 2019.
PMID: 31145643
We identified 37 FDA-approved compounds that specifically kill cancer cells in the high-HES3-expression conditions. Our work reveals a novel signaling state in cancer, biomarkers, a strategy to identify treatments against it, and a set of putative drugs for p …
We identified 37 FDA-approved compounds that specifically kill cancer cells in the high-HES3-expression conditions. Our work reveals a …